Skip to main content
TheraVet SA logo

TheraVet SA — Investor Relations & Filings

Ticker · ALVET ISIN · BE0974387194 LEI · 984500804EBR3F1EFF71 BR Manufacturing
Open in API
Filings indexed 239 across all filing types
Latest filing 2024-03-13 Regulatory Filings
Country BE Belgium
Listing BR ALVET

About TheraVet SA

https://www.egeiro.com/

TheraVet SA is a veterinary biotechnology company specializing in the development and commercialization of treatments for osteoarticular diseases in companion animals. The company focuses on creating a portfolio of pharmaceutical products and solutions designed to manage bone and joint conditions, such as osteoarthritis. Its primary objective is to provide innovative therapeutic options to improve the mobility and quality of life for pets.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 100% confidence The document is a press release dated March 13, 2024, announcing the launch of a new product line, BIOCERA-VET® Equine, for the veterinary market. It details the product's availability, features, and target applications (dental and orthopedic care for horses). This type of announcement, focusing on a specific business development (product launch) rather than comprehensive financial results (10-K, IR, ER) or mandatory regulatory filings, typically falls under general corporate news. Since there is no specific category for a 'Product Launch Announcement' and it is not a transcript (CT), director dealing (DIRS), dividend notice (DIV), or capital change (CAP), the most appropriate general category for a significant, non-mandatory corporate update that doesn't fit elsewhere is 'Regulatory Filings' (RNS), which serves as a broad category for miscellaneous announcements, or potentially an 'Earnings Release' (ER) if it were tied to financial reporting, but here it is purely operational/commercial news. Given the context of a press release announcing a commercial milestone, RNS is the best fit as a general regulatory/corporate announcement fallback.
2024-03-13 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release dated February 20, 2024, announcing that TheraVet has hired Brakke Consulting to help develop its growth strategy for the US market, including potential M&A activities. This type of announcement, detailing strategic business decisions, management actions (hiring consultants for strategy), and future plans, is characteristic of a general corporate announcement or press release. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR). Since it announces a significant strategic move and is presented as a news item, it fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate announcement, or potentially 'Management Reports' (MDA) if it were a more detailed management discussion, but RNS serves as the best general corporate news fallback here, as it is a public announcement of a strategic mandate.
2024-02-20 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release dated February 20, 2024, announcing that TheraVet has retained Brakke Consulting to strategize growth in the US market, including assessing M&A opportunities. This type of announcement, detailing strategic business developments, partnerships, or corporate strategy updates that are not standard periodic financial reports (like 10-K or IR), typically falls under general corporate news or regulatory filings. Since the content focuses on strategic business development and potential M&A assessment rather than a formal M&A bid (TAR), management changes (MANG), or financing (CAP), it is best classified as a general announcement. Given the options, 'Regulatory Filings' (RNS) serves as the appropriate fallback for significant, non-standard corporate news releases that don't fit the more specific categories like ER, DIV, or MANG. It is not a formal financial report, earnings release, or proxy statement.
2024-02-20 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 100% confidence The document is a press release dated January 30, 2024, announcing that TheraVet has been granted a patent for its VISCO-VET technology in Europe, Israel, and Singapore. The content focuses on intellectual property protection and ongoing clinical trials, which are typical subjects for general corporate announcements or investor relations updates. Since it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR), and it directly relates to the company's core assets (patents), it fits best under the general category for corporate news that doesn't fit elsewhere, which is Regulatory Filings (RNS), or potentially Investor Presentation (IP) if it were a slide deck, but this is a text announcement. Given the nature of patent grants being material news, RNS is the most appropriate general regulatory announcement category when a more specific IP filing code is not available. It is not a proxy statement (DEF 14A), management discussion (MDA), or capital action (CAP).
2024-01-30 French
Inside Information / Other news releases
Regulatory Filings Classification · 100% confidence The document is a press release announcing that TheraVet has been granted a patent for its VISCO-VET technology in Europe, Israel, and Singapore. This announcement relates directly to the company's intellectual property portfolio and technological development. Among the provided categories, 'Intellectual Property' (IP) is the most fitting classification for a patent grant announcement, as it directly concerns the protection of the company's innovations. It is not an earnings release (ER), a major regulatory filing (like 10-K), or a management change (MANG).
2024-01-30 English
PR_TheraVet_Q4 2023_EN_23012023_EN.pdf
Earnings Release Classification · 95% confidence The document is a press release from TheraVet announcing sales performance figures for its BIOCERA-VET product line for the fourth quarter of 2023. It highlights key performance metrics (percentage increases in units sold) and provides management commentary. It is not a full quarterly report (IR) but rather an initial announcement of specific financial highlights, which fits the definition of an Earnings Release (ER). Q4 2023
2024-01-23 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.